JAWS Spitfire Acquisition Corporation Announces Special General Meeting Teleconference Details

MIAMI, September 22, 2021– (COMMERCIAL THREAD) – JAWS Spitfire Acquisition Corporation (“JAWS Spitfire“) (NYSE: SPFR), announced today that due to public health and safety concerns related to the current coronavirus (COVID-19) pandemic, it is highly encouraging for shareholders to attend the meeting General Meeting of its shareholders, to be held on September 28, 2021 at 9:00 a.m. New York time (the “General assembly“), by teleconference rather than in person. The purpose of the General Assembly is to vote on certain proposals relating to the previously announced merger between JAWS Spitfire and Velo3D, Inc. (“BIKE3d“or the”Society“), the related Business Combination Agreement, dated March 22, 2021 (as amended or supplemented from time to time, on”Business combination agreement“), and the other transactions contemplated therein (collectively, the”Commercial combination“).

The General Assembly will be accessible via a live audio webcast at https://www.cstproxy.com/jawsspitfire/2021 or by calling 1 888 965-8995 (toll free — North America) or +1 415-655-0243 (International). Shareholders will be able to submit a question to the management of JAWS Spitfire online prior to the meeting on the general meeting website. https://www.cstproxy.com/jawsspitfire/2021 or live during the meeting.

About Velo3D, Inc.

BIKE3d allows companies to imagine more and additively manufacture almost anything. Bringing together an integrated end-to-end solution of software, hardware and process control innovations, VELO3D ‘Metal 3D printing technology provides unmatched quality control for mass production and improved part performance. With BIKE3d Flow ™ print preparation software, Sapphire® laser powder bed AM system and Assure ™ quality assurance software, manufacturers can accelerate product innovation, become more agile and responsive to market needs and reduce costs. The first in the industry to introduce SupportFree metal 3D printing, which enables the fabrication of previously impossible geometries, the company is based in Silicon Valley and is privately funded. BIKE3d was named to Fast Company’s prestigious annual list of the world’s most innovative companies for 2021. For more information, please visit https://www.velo3d.com/.

About JAWS Spitfire Acquisition Corporation

JAWS Spitfire Acquisition Corporation, led by Chairman Barry S. Sternlicht and Chief Executive Officer Matthew Walters, is a blank check company incorporated as a Cayman Islands exempt corporation for the purpose of effecting a merger, exchange of ‘shares, an acquisition of assets, a purchase of shares, a reorganization or similar business combination with one or more companies or entities.

Additional information

In connection with the business combination, JAWS Spitfire has filed, and the SEC has declared effective, a registration statement on Form S-4 containing a proxy circular / final prospectus. JAWS Spitfire has sent the Management Proxy Circular / Final Prospectus and other relevant documents relating to the business combination to its shareholders. This Current Report does not contain all the information that should be taken into account regarding the Business Combination and is not intended to form the basis of an investment decision or any other decision regarding the Business Combination. Investors and holders of securities of JAWS Spitfire are encouraged to read the proxy circular / final prospectus in connection with the solicitation of proxies of JAWS Spitfire for the General Meeting to be held to approve the business combination. other documents filed in connection with the business combination, as these documents will contain important information about the business combination and the parties to the business combination. The Proxy Circular / Final Prospectus was sent to the shareholders of JAWS Spitfire on the registration date of August 27, 2021; shareholders who hold their shares in registered form have the right to vote for their shares held on the day of the General Meeting. Shareholders may also obtain free copies of the Proxy Circular / Final Prospectus and other documents filed with the SEC on the SEC website at www.sec.gov or by directing a request to: JAWS Spitfire Acquisition Corporation, 1601 Washington Avenue, Suite 800, Miami Beach, FL 33139.

Participants in the call for tenders

JAWS Spitfire, the Company and their respective directors, officers, other officers and employees, under the rules of the SEC, may be considered participants in the solicitation of proxies from the shareholders of JAWS Spitfire in connection with the Combination. companies. Investors and security holders can obtain more detailed information regarding the names and interests in the business combination of the directors and officers of JAWS Spitfire in the documents filed by JAWS Spitfire with the SEC, including the proxy circular. / the final prospectus of JAWS Spitfire for the business combination.

The Company and its directors and officers may also be considered participants in the solicitation of proxies from the shareholders of JAWS Spitfire in connection with the Business Combination. A list of the names of such directors and officers and information regarding their interests in the business combination is included in the proxy circular / final prospectus for the business combination.


This current report is not a statement of proxy or a solicitation of proxy, consent or authorization with respect to any security or with respect to the potential transaction and does not constitute an offer to sell or a solicitation of an offer to purchase securities of JAWS Spitfire or the Company, and there shall be no sale of such securities in any state or jurisdiction in violation of applicable law. No offer of securities will be made except by means of a prospectus meeting the requirements of the securities law.

Forward-looking statements

Certain statements made in this report are not historical facts but are forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually accompanied by words such as “to believe, “”may, “”will, “”estimate, “”Carry on, “”to anticipate, “”intend, “”wait, “”should, “”would have, “”plan, “”to predict, “”potential, “”appear, “”to look for, “”future, “”outlook“and similar expressions which predict or indicate future events or trends or which are not statements about historical matters. These forward-looking statements include, without limitation, statements concerning future events, business combinations between JAWS Spitfire and the company, the estimated or anticipated future results and benefits of the combined company as a result of the business combination, including the likelihood and ability of the parties to successfully complete the business combination, future opportunities for the combined company and other statements that are not historical facts.

These statements are based on the current expectations of JAWS Spitfire management and are not actual performance predictions. These forward-looking statements are provided for informational purposes only and are not intended to serve as a guarantee, assurance, prediction or definitive statement of fact or probability to an investor and should not be relied upon by an investor. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many real events and circumstances are beyond the control of JAWS Spitfire and the Company. These statements are subject to a number of risks and uncertainties relating to the business of JAWS Spitfire and the business combination, and actual results could differ materially. These risks and uncertainties include, without limitation, general economic, political and business conditions; the inability of the parties to complete the Business Combination or the occurrence of any event, change or other circumstances which could result in the termination of the Business Combination Agreement; the outcome of any legal proceedings that may be initiated against the parties following the announcement of the Business Combination; receiving an unsolicited offer from another party for an alternative business transaction that could interfere with the business combination; the risk that the approval of the shareholders of JAWS Spitfire or of the Company for the potential transaction will not be obtained; failure to realize the expected benefits of the business combination, including due to a delay in completing the potential transaction or difficulty integrating the business of JAWS Spitfire and the Company; the risk that the Business Combination will disrupt current plans and operations following the announcement and completion of the Business Combination; the combined ability of the business to grow and manage its growth profitably and to retain key employees; the amount of redemption requests made by shareholders of JAWS Spitfire; the inability to obtain or maintain the listing of the company’s shares post-acquisition on NYSE following the Business Combination; costs related to the Business Combination; and the factors discussed in the JAWS Spitfire proxy circular / final prospectus relating to the business combination, including those under “Risk Factors” and other documents filed with the SEC. There may be additional risks that JAWS Spitfire is not currently aware of or that JAWS Spitfire currently considers to be immaterial, which could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide JAWS Spitfire’s expectations, plans or forecasts regarding future events and opinions as of the date of such communication. JAWS Spitfire anticipates that subsequent events and developments will cause JAWS Spitfire ratings to change. However, although JAWS Spitfire may choose to update these forward-looking statements at some time in the future, JAWS Spitfire expressly disclaims any obligation to do so. These forward-looking statements should not be taken as representing evaluations of JAWS Spitfire as of a date after the date of this communication.

Nothing in this current report should be construed as a representation by any person that the forward-looking statements set forth herein, including the expected results of such forward-looking statements, will be achieved. Therefore, one should not place undue reliance on forward-looking statements.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210922005970/en/


For BIKE3d:
Renette Youssef
Marketing Director
[email protected]

For JAWS Spitfire Acquisition Corporation:
Abernathy Mac Gregor
Tom Johnson / Dan Scorpion
[email protected] / [email protected]
(212) 371-5999 / (646) 899-8118

Source link

ASGN Incorporated: ECS unit obtains contract with Naval Information Warfare Center to consolidate old health records

Newswires MT 2021


Analyst Recommendations on ASGN INCORPORATED
Sales 2021 3 947 million

Net income 2021 216 million

Net debt 2021 114 million

PER 2021 ratio 20.8x
Yield 2021
Capitalization 5,871 million
5,871 million
VE / Sales 2021 1.52x
VE / Sales 2022 1.32x
Number of employees 4,200
Free float 96.9%

Duration :


ASGN Incorporated Technical Analysis Chart |  MarketScreener

ASGN INCORPORATED Technical Analysis Trends

Short term Mid Road Long term
Tendencies Bullish Bullish Bullish

Evolution of the income statement

To sell

To buy

Average consensus SURPASS
Number of analysts 7
Last closing price

$ 110.98

Average price target

$ 118.67

Spread / Average target 6.93%
Source link

Five strong organizations renamed to form Teijin Automotive Technologies | State

  • Continental Structural Plastics, Inapal, Benet, CSP Victall and Teijin Automotive Center Europe are now unified under a single brand called Teijin Automotive Technologies
  • Teijin Automotive Technologies, in the same way Teijin Automotive Composites team at Japan, becomes the world leader in the manufacture of advanced products for automobiles, heavy trucks, marine and recreational vehicles
  • The unique organization has a global footprint and the ability to create solutions that make vehicles safer and more environmentally friendly

AUBURN HILLS, Michigan., September 22, 2021 / PRNewswire / – Five strong organizations – Continental Structural Plastics (CSP), Inapal Plásticos, Benet Automotive, CSP Victall and Teijin Automotive Center Europe (TACE) – have come together under one brand to form Teijin Automotive Technologies, a global leader in composite materials and solutions for the global mobility industry.

Through this rebranding, Teijin Automotive Technologies becomes a proven manufacturer of high tech materials for dynamic market divisions with the ability to deliver consistent materials and components to customers across North America, Europe and Asia – a capacity that no other supplier can provide. Covering several mobility-related industries including automotive, heavy-duty truck, marine and recreational vehicle segments, the new organization which includes Teijin’s automotive composites team in Japan, is positioned to provide advanced materials solutions through its 29 strategically located manufacturing and technical centers. Using all the strengths of previously separated companies, Teijin Automotive Technologies can provide unique solutions for the next generation of mobility.

“With the integration of these organizations, we can provide expertise in a wide range of materials, which allows us to develop solutions that meet our customers’ most difficult design challenges,” said Steve rooney, CEO of Teijin Automotive Technologies and Managing Director, Teijin Composites Business Unit. “Now, as Teijin Automotive Technologies, we are able to develop new materials, find them where and when they are needed, and provide the expertise that meets the world’s ever-changing mobility needs. “

This decision establishes a singular organization with a global footprint and 5,400 employees able to combine world-class materials expertise with cutting-edge engineering and design to create solutions that make vehicles safer and more environmentally friendly. By selecting the right material for the right application, Teijin Automotive Technologies creates components and systems that make vehicles lighter, stronger, safer and more energy efficient. This unification further strengthens the organization’s capabilities as a vertically integrated full service provider that develops materials to meet the needs of today’s customers, while anticipating the needs of tomorrow.

As an organization committed to sustainability and innovation, Teijin Automotive Technologies is currently engaged in a variety of research projects aimed at making its operations and products more environmentally friendly. These include carbon footprint analyzes, a comprehensive life cycle assessment of composite materials and material recycling processes.

“Teijin has a very strong commitment to sustainability and the society of the future, so we are engaged in a number of initiatives that support this commitment,” Rooney explained. “By identifying the sources of CO2 emissions in our materials and processes, we will identify ways to reduce our environmental impact and set long-term improvement goals.”

Teijin Automotive Technologies’ innovation awards include Automotive News PACE Awards, JEC Innovation Awards, several CAMX and SPE Innovation Awards and the General Motors Supplier Innovation Award.

About Teijin Automotive Technologies

Teijin Automotive Technologies specializes in the development and production of advanced composite components – including carbon and glass fiber – for the global automotive and transportation industries and is an integral part of the Teijin group of companies. The company is a global leader in composite formulations with a focus on providing automotive manufacturers with lightweight, durable products that allow flexibility in design and packaging. Based at Auburn Hills, Michigan., United States, Teijin Automotive Technologies has 29 establishments in 8 countries and employs more than 5,000 people. For more information, visit teijinautomotive.com.

Rocket Companies Announces Increase and Pricing of Senior Notes Due 2026 and Senior Notes Due 2033

About the Teijin Group

Teijin (TSE: 3401) is a global technology-driven group providing advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health awareness. Originally created as from Japan first rayon manufacturer in 1918, Teijin has grown into a unique enterprise encompassing three main business areas: high performance materials including aramid, carbon fibers and composites, as well as resin and plastic processing, films, polyester fibers and product processing; health care, including pharmaceuticals and home care equipment for bone / joint, respiratory and cardiovascular / metabolic diseases, nursing and pre-symptomatic health care; and IT, including B2B solutions for healthcare, enterprise and public systems, as well as B2C software packages and online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions”, Teijin aims to be a company that supports the society of tomorrow. The group comprises more than 170 companies and employs some 20,000 people in 20 countries around the world. Teijin achieved a consolidated turnover of JPY 836.5 billion ($ 7.7 billion) and the total assets of JPY 1,036.4 billion ($ 9.5 billion) during the fiscal year ended March 31, 2021.


Kim zitny

+1 248.535.6944

[email protected]

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/five-strong-organizations-rebranded-to-form-teijin-automotive-technologies-301382774.html

SOURCE Teijin Automotive Technologies

Source link

Guidelines for the new medical device law (Taiwan)

Medical devices were previously governed by the Pharmaceutical Affairs Act. On December 13, 2019, the Legislative Yuan passed the “Medical Device Law” (the “Law”) through the third reading process, separating the governance of these medical devices from the “Pharmaceutical Affairs Law” . This distinction highlights an independent resolution for a more complete regulation system that meets the practical needs of medical device management in order to accelerate their introduction to the market and promote its industrial development. The law entered into force on May 1, 2021 and its relevant rules and standards have been made public. (See appendix for more details)

The law consists of 9 chapters and 85 articles. Its key points are:

I. Regulation of medical device companies

As stipulated in the Pharmaceutical Affairs Act, medical device companies consist of two categories: manufacturers and resellers. The new law made several important improvements to accommodate the trend towards a finer division of the manufacturer. Specifically, he clarified the definition of manufacturer to include the manufacture, packaging, labeling, sterilization and final inspection of medical devices and added to the definition of manufacturer “engage in the design of devices”. medical devices and market the devices under their name ”(article ten). In addition, the law required those involved in the manufacture, import or maintenance of medical devices to recruit technicians according to the type of devices used (Article 15).

The law categorizes resellers as wholesale, retail, import, export, rental and service, and these resellers are required to apply to serve as medical device companies before undertaking such activities. (Articles 11 and 13)

II. Improve the regulation of risk classification before the marketing of medical devices

In principle, medical devices must be the subject of an inspection registration request; It is only after approval and licensing that it can be manufactured and imported. However, the new law simplifies this pre-market review process for low-risk medical devices. Instead of requesting inspection registration, the device list will suffice for several low-risk medical devices. Manufacturers must file an annual declaration of registration with the competent central authority each year to maintain its validity. (Articles 25, 28)

The issuance of licenses for medical devices is flexible as to its period of validity. The maximum validity period is 5 years and extensions can be applied before the expiration date. Each extension must not exceed 5 years. (Article 27).

III. Implementation of regulations on pre-market clinical trials of medical devices

Clinical trial institutions or trial sponsors submit an application for approval to the central authority before any clinical trial. Any adverse event during the trials must be reported to the authority within 7 days of becoming aware of these events. If security risks arise during the trial, it can be suspended or terminated (Articles 37, 38, 39).

To manage the risks, clinical trials on medical devices that carry insignificant risks as announced by the competent central authority are not required to submit requests for approval (Article 37).

IV. Improve post-market supervision on the safety of medical devices

The competent authority announces specific categories and articles of medical devices with restriction of their type of sale or supply in response to various new forms of sale of medical devices (Article 18). With respect to medical devices classified as a specific risk level as announced by the competent authority, medical device companies and medical establishments should establish data on the source and flow of their products to help trace and monitor products on the market (Article 19).

For product safety considerations, the manufacturer of medical devices must establish a quality control system and report to the competent central authority for inspection in order to obtain authorization before proceeding with manufacture (Article 22). Medical devices and their resellers announced by the competent authority must set up a quality distribution system that meets the distribution standards for medical devices, and obtain a distribution authorization before any wholesale, import or export (Article 24) . In addition, a communication protocol should be established for essential medical devices, especially when their manufacture, import ceases or supply is insufficient. (article 34)

To oversee the management of medical devices, taking into account the potential risk of certain medical devices, the competent authority may order medical device companies to execute a safety oversight plan on specified items at a time of their choosing. in order to monitor the safety of medical devices. Medical institutions provide assistance and provide all relevant data (Article 47). In addition, for the safety of its users, as soon as it becomes aware of a probable risk of bodily harm from a medical device, the authorized owner or the registrant of such devices must immediately take corrective measures and preventive measures and inform the competent authority (Article 49).

V. Criminal liability of serious offenders

Those who violate the law will be subject to administrative penalties depending on the nature of the violation, which may include fines; an order requiring corrective action within a limited timeframe; an announcement of the identity, name and details of the infringement of the offender; and license suspension or withdrawal (Articles 64 to 71). The following penal sanctions may apply to persons in serious breach:

1. Those who manufacture or import defective medical devices which lead to a misdiagnosis, or devices containing toxic or dangerous substances which cause bodily harm may be sentenced to a maximum of 5 years imprisonment, criminal detention or imprisonment. fine of up to NT $ 50 million, or both. Negligent violations can be sentenced to a maximum of 3 years imprisonment, criminal detention or a fine of up to NT $ 10 million, or both. (Article 60, paragraphs 1 and 3)

2. Those who knowingly sell, supply, transport, store, trade, transfer or display with the intention of selling defective medical devices may be sentenced to a maximum of 3 years imprisonment, criminal detention or a fine of up to NT $ 10 million. , or both. Negligent violations can be sentenced to criminal detention or a fine of up to NT $ 1 million, or both. (Article 60, paragraphs 2 and 4)

3. Anyone who abuses or uses without authorization the name, instructions or labels of a legitimate medical device can be sentenced to up to 5 years imprisonment, criminal detention or a fine of up to $ 20 million. NT, or both. Those who knowingly import, sell, supply, transport, store, trade, transfer or display with the intention of selling medical devices while being aware of the above violations may be sentenced to a maximum of 2 years imprisonment, detention criminal or fine of up to NT $ 10 million, or both. (Article 61)

4. Anyone attempting to sell or supply, manufacture or import unapproved medical devices or unregistered devices that should have been registered; and those who knowingly sell, provide, transport, store, trade, transfer or display with the intention of selling while being aware of the above violations may be sentenced to a maximum of 3 years imprisonment, criminal detention or a fine of up to NT $ 10 million, or both. (article 62)

5. In the event that those who, in the exercise of their duty, have violated the aforementioned offenses are the representative, agent, employee or any other member of the personnel of a legal person or a natural person , in addition to the penalties imposed on the offender, said legal / natural person will be liable to a maximum of ten times the fine provided for in all articles. (Article 63)

Annex: Compilation of relevant sub-laws authorized under the Act

Source link

SynAgile Corporation Announces Completion of Funding, Appointment of Mr. Michael McNamara to … | national

WILSON, Wyoming, September 22, 2021 (GLOBE NEWSWIRE) – SynAgile Corporation ( www.SynAgile.com ), a private pharmaceutical company that develops and markets drug delivery systems using its proprietary OraFuse® technology platform, today announced the closing of a convertible debt investment of more than $ 9 million . Proceeds from the sale will be used to complete the Phase 2 clinical trial of the DopaFuse® Delivery System and initiate larger scale production for its Phase III trial. The Phase II trial is currently underway in Luxembourg, Italy and Spain. The DopaFuse delivery system is the first non-invasive and continuous delivery system for levodopa-carbidopa. DopaFuse has the potential to treat motor fluctuations and dyskinesias associated with Parkinson’s disease.

Along with the funding, Mr. Michael McNamara joined the SynAgile Board of Directors. Mr. McNamara spent 12 years as CEO of Flex, one of the world’s largest multinational technology manufacturing companies, where he grew the company to $ 25 billion in revenue and over 200,000 employees operating in more than 30 countries. Mr. McNamara sits on the boards of Carrier, Workday and PCH International, and has served on the boards of many other companies, including Slack Technologies, Delphi, SunEdison and Therasense. He is also a venture capital partner at Eclipse Ventures.

SynAgile also announces the appointment of Dr. C. Warren Olanow as Medical Director of SynAgile. Dr Olanow has been an advisor to SynAgile since 2011. He is the past chair of the Department of Neurology at the Mount Sinai School of Medicine in New York. Dr. Olanow is the co-founder and CEO of Clintrex, a clinical research company. Dr. Olanow’s research has focused on the cause and treatment of PD and other neurodegenerative diseases. He has led several pivotal clinical trials leading to the approval of numerous drugs and is the recipient of the 2013 American Academy of Neurology Movement Disorders Research Award and Lifetime Achievement Award from the International Parkinson and Movement Disorder Society.

About SynAgile

SynAgile is a pharmaceutical company focused on the development and commercialization of therapeutic products using its patented continuous, non-invasive oral dosing technology, OraFuse®, initially focusing on the treatment of debilitating motor complications in patients with Parkinson’s disease using its DopaFuse® levodopa-carbidopa delivery system.

SOURCE SynAgile Corporation

Contact SynAgile Corporation Ephraim Heller [email protected]

Copyright 2021 GlobeNewswire, Inc.

Source link

Over 150 industry leaders and organizations call for decisive government action to enable the full decarbonization of international shipping by 2050

Signatories of the Call to Action on Decarbonizing Shipping urge world leaders to align shipping with the Paris Agreement temperature target. The private sector is already taking important steps to decarbonize global supply chains. Governments now need to implement policies that will energize the transition and make zero-emission shipping the default choice by 2030.

Copenhagen, Denmark, September 21, 2021 / PRNewswire / – The complete decarbonization of international shipping is urgent and achievable. This is the clear message from over 150 industry leaders and organizations representing the entire maritime value chain, including shipping, freight, energy, finance, ports and infrastructure. In conjunction with the United Nations General Assembly and upstream of critical climate negotiations in COP26 in Glasgow in November, they call on governments to work with industry to put in place the policies and investments needed to reach critical tipping points in the decarbonization of global supply chains and the global economy.

The signatories of the Call to Action for Decarbonizing Shipping include some of the world’s largest players in global trade: AP Moller – Maersk, BHP, BP, BW LPG, Cargill, Carnival Corporation, Citi, Daewoo Shipbuilding & Marine Engineering, Euronav, GasLog, Hapag-Lloyd, Lloyd’s Register, Mitsui OSK lines, MSC Mediterranean Shipping Company, Olympic Shipping and Management, Panama Canal Authority, Port of Rotterdam, Rio Tinto, Shell, Trafigura, Ultranav, Volvo and Yara.

Ships carry around 80% of global trade and account for around 3% of global greenhouse gas (GHG) emissions. In 2018, the UN’s International Maritime Organization (IMO) adopted a first GHG strategy. It aims to reduce total annual GHG emissions from international shipping by at least 50% from 2008 levels by 2050. The strategy is expected to be revised in 2023.

“Now is the time to elevate our ambitions and align shipping around the world – a major carrier of global trade – with the goals of the Paris Agreement. We are working closely with our customers to advance the shipping industry’s transition to net zero emissions and, with the support of strong policy measures, we can accelerate our collective efforts to decarbonise the global economy, “ said Jane fraser, CEO of Citi.

The private sector is already taking concrete steps to decarbonize maritime transport. This includes investing in R&D and pilot projects, ordering and building carbon-neutral operated vessels, purchasing zero-emission shipping services, investing in the production of net-emission fuels. zero, investment in port and bunkering infrastructure, and assessment and disclosure of the climate alignment of maritime transport. related activities.

“For the world to decarbonize, maritime transport must decarbonise. Our customers look to us to decarbonise their supply chain emissions. We invest heavily in carbon neutral emissions technologies that are readily available. To make these investments the default choice in our industry, we need a market-based measure to close the competitive gap between today’s fossil and zero-emission fuels and carbon-neutral fuels. of tomorrow “, said Henriette Hallberg Thygesen, CEO, Fleet and Strategic Brands, AP Moller – Maersk.

“Decarbonizing shipping is both critical to achieving zero net global emissions and increasingly urgent. Policymakers have a historic opportunity to accelerate this process by introducing a global carbon tax on marine fuels, to stimulate decarbonization and incentivize investment in zero emission fuels and ships. The time for action is now ”, says Jeremy Weir, Executive Chairman and CEO of Trafigura.

“Decarbonizing maritime transport must not leave any country behind. To make the transition to maritime transport and zero-emission fuels fair and inclusive, policy measures must ensure that decarbonization of maritime transport also creates jobs and opportunities for people in developing countries and emerging economies. ” said Johannah christensen, CEO of the World Maritime Forum.

The signatories of the Call to Action for Decarbonizing Maritime Transport call on world leaders to:

Commit to decarbonizing international maritime transport by 2050 and provide a clear and fair implementation plan to achieve this when adopting the IMO’s GHG strategy in 2023.

Support zero-emission maritime transport projects on an industrial scale through national action, for example by setting clear decarbonisation targets for inland maritime transport and by offering incentives and support to early adopters and wider deployment of zero emission fuels and ships.

Put in place policy measures that will make zero-emission shipping the default choice by 2030, including significant market-based measures, coming into effect by 2025, that can support the commercial deployment of zero-emission ships and fuels in international shipping.

The Call to Action for Decarbonizing Shipping was developed by a multi-stakeholder working group convened by the Getting to Zero coalition – a partnership between the World Maritime Forum, the World Economic Forum and Friends of Ocean Action. Members of the task force include Cargill Ocean Transportation, Citi, the COP26 Climate Champions Team, Energy Transitions Commission, Lloyd’s Register, Port of Antwerp, Torvald Klaveness, Trafigura, Yara and UMAS.

Learn more about the Call to Action for Decarbonizing Shipping and view the full list of signatories here.

Learn more on the concrete actions that the signatories of the Call to Action for the Decarbonization of Maritime Transport are taking here to support the decarbonization of maritime transport.

More information :
Sophie rud
Senior Communications Advisor
[email protected]
+45 28102332


View original content: https://www.prnewswire.com/news-releases/over-150-industry-leaders-and-organizations-call-for-decisive-government-action-to-enable-full-decarbonization-of – international-shipping-by-2050-301379995.html

SOURCE World Maritime Forum

Source link

Coupa Software Incorporated (NASDAQ: COUP) CEO Sells $ 12,167,500.00 In Stock

Coupa Software Incorporated (NASDAQ: COUP) CEO Robert Bernshteyn sold 50,000 shares of the company in a trade that took place on Friday, September 17. The shares were sold at an average price of $ 243.35, for a total trade of $ 12,167,500.00. The sale was disclosed in a file with the Securities & Exchange Commission, accessible through this link.

Robert Bernshteyn also recently completed the following transactions:

  • On Tuesday August 17, Robert Bernshteyn sold 50,000 shares of Coupa Software. The shares were sold at an average price of $ 207.52, for a total transaction of $ 10,376,000.00.
  • On Monday July 19, Robert Bernshteyn sold 50,000 shares of Coupa Software. The stock was sold at an average price of $ 219.29, for a total trade of $ 10,964,500.00.

NASDAQ: COUP shares traded at $ 2.37 in Tuesday’s noon session, reaching $ 243.63. The stock had a trading volume of 2,023,640 shares, compared to its average volume of 1,269,875. The company’s 50-day moving average price is $ 230.60 and its 200-day moving average price is of $ 244.93. The company has a market cap of $ 18.04 billion, a P / E ratio of -56.55 and a beta of 1.44. The company has a quick ratio of 0.79, a current ratio of 0.79, and a debt ratio of 0.97. Coupa Software Incorporated has a 52 week low of $ 203.51 and a 52 week high of $ 377.04.

(A d)

Investors must see the lucrative potential of $ 227 billion to transform the game forever.

Coupa Software (NASDAQ: COUP) last released its quarterly earnings data on Monday, September 6. The tech company reported earnings per share (EPS) of $ 0.26 for the quarter, beating the Zacks consensus estimate of ($ 0.06) by $ 0.32. The company posted revenue of $ 179.25 million in the quarter, compared to analysts’ expectations of $ 162.98 million. Coupa Software posted a negative net margin of 48.86% and a negative return on equity of 17.63%. The company’s quarterly revenue increased 42.3% compared to the same quarter last year. During the same period of the previous year, the company achieved EPS of $ 0.21. Research analysts expect Coupa Software Incorporated to post -2.45 EPS for the current fiscal year.

A number of hedge funds have recently increased or reduced their holdings in the stock. Clarius Group LLC strengthened its position in Coupa Software by 2.9% during the 2nd quarter. Clarius Group LLC now owns 1,799 shares of the tech company valued at $ 472,000 after purchasing an additional 50 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG increased its position in Coupa Software by 5.0% in the second quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 1,045 shares of the tech company valued at $ 274,000 after purchasing an additional 50 shares in the last quarter. Fernwood Investment Management LLC strengthened its position in Coupa Software by 1.1% in the 2nd quarter. Fernwood Investment Management LLC now owns 6,015 shares of the technology company valued at $ 1,577,000 after acquiring 65 additional shares during the period. Penserra Capital Management LLC strengthened its position in Coupa Software by 39.2% in the 2nd quarter. Penserra Capital Management LLC now owns 238 shares of the tech company valued at $ 62,000 after acquiring 67 additional shares during the period. Finally, Corient Capital Partners LLC strengthened its position in Coupa Software by 5.5% in the second quarter. Corient Capital Partners LLC now owns 1,287 shares of the tech company valued at $ 337,000 after acquiring 67 additional shares during the period.

A number of equity analysts have recently weighed on COUP stocks. TheStreet reduced Coupa Software’s stock from a “c-” rating to a “d +” rating in a research report published on Monday, August 2. Mizuho raised his price target for Coupa Software shares from $ 250.00 to $ 280.00 and rated the company “neutral” in a research note on Wednesday, September 8. They noted that the move was an appraisal call. Truist Securities lowered its price target on Coupa Software stock from $ 386.00 to $ 326.00 and set a “buy” rating on the stock in a research note on Tuesday, June 8. Morgan Stanley lowered its price target for Coupa Software shares from $ 381.00 to $ 345.00 and set an “overweight” rating for the company in a research report released on Friday, July 16. Finally, Oppenheimer raised its price target for Coupa Software shares from $ 260.00 to $ 300.00 and gave the company an “outperformance” rating in a research report published on Wednesday, September 8. One equity research analyst rated the stock with a sell rating, nine gave the conservation rating, eleven issued a buy rating, and one gave the stock a strong buy rating. Based on data from MarketBeat.com, Coupa Software currently has a consensus rating of “Buy” and an average target price of $ 298.18.

About Coupa Software

Coupa Software, Inc is committed to providing enterprise expense management (BSM) solutions. Its products include invoices, expenses, salaries, expense analysis, strategic sourcing, labor contract management and supplier management. The company was founded by Noah Eisner and Dave Stephens in 2006 and is headquartered in San Mateo, California.

Read more: Growth and Income Fund

Insider Buys and Sells by Quarter for Coupa Software (NASDAQ: COUP)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Coupa Software now?

Before you consider Coupa Software, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and Coupa Software was not on the list.

While Coupa Software currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Source link

Of the. Supreme Court drops risky precedent over direct shareholder claims

A person enters the Delaware Supreme Court in Dover, Delaware, United States, June 10, 2021. REUTERS / Andrew Kelly

The company and law firm names shown above are generated automatically based on the text of the article. We are improving this functionality as we continue to test and develop in beta. We appreciate comments, which you can provide using the comments tab on the right of the page.

(Reuters) – It is a bold strategy to argue in a nonsuit motion that the binding precedent is bogus and should be overturned. Bold too? Arguing that the precedent can be rejected in an interlocutory appeal, even before there is a decision on the merits of the case.

However, this is what Weil, Gotshal & Manges proposed last year at Delaware Chancery Court, where its client, Brookfield Asset Management Inc, was facing claims for breach of duty on the part of shareholders of TerraForm Power Inc.

The shareholder lawsuit, as I will explain, was based entirely on the 2006 Delaware Supreme Court decision in Gentile v. Rossette. Gentile allowed minority shareholders, in limited circumstances, to bring direct claims against majority shareholders instead of suing on behalf of the company in a more procedurally complex derivative claim.

by Weil motion to dismiss Brookfield’s lawsuit argued that the Supreme Court’s Gentil precedent led to confusion and inconsistency. The decision should be “dismissed,” the brief said, “including, if necessary, via an interlocutory appeal.”

This is exactly how the litigation unfolded. Last October, Vice-Chancellor Sam Glasscock refuse Brookfield’s motion to dismiss, citing Gentile even as he acknowledged “lingering uncertainty as to whether (the ruling) remains good law.” Weil asked Glasscock to certify an interlocutory appeal to resolve this uncertainty. The Vice Chancellor sent the appeal to the Delaware judges.

And Monday, at Brookfield Asset Management Inc. v. Rosson, the Delaware Supreme Court unanimously overturned its own precedent in Gentile, ruling that the 2006 ruling created a contradictory and unnecessary exception to the test that establishes whether shareholder claims are direct or derivative.

The decision means that shareholders can no longer directly sue controlling shareholders for diluting their stock value and voting rights. These claims, the court concluded, can only be made under the Supreme Court’s 2004 test in Tooley v. Donaldson, Lufkin & Jenrette Inc because the harm to individual shareholders arises from the harm done to the company, and any recovery for shareholders would flow from the recovery of the company.

The 2006 Nations Court ruled that the exception it created – allowing minority shareholders to bring direct claims against controllers who act to expand their ownership – “fits perfectly into… Tooley”. In Monday’s opinion overthrowing Gentile, the Delaware judges said the 15 years since have shown that “the ‘fit’ is not that ‘comfortable.’

“We do not intend to disrespect any previous panel of this tribunal,” wrote Judge Karen Valihura. “On the contrary, we recognize that the law must evolve through trial and error, through the tests of time and practical application.”

Monday’s ruling ends the case against Weil Gotshal’s client. Shareholders alleged that in 2018, the Brookfield entities underpaid the TerraForm shares they acquired in a $ 650 million private placement that increased Brookfield’s stake in the company. green energy from 51% to 63.5%. A Brookfield entity acquired the remaining public shares in 2020, depriving minority shareholders of the right to bring derivative actions arising from the private placement. Thus, the only chance of recovery for the plaintiffs was a direct lawsuit against Brookfield.

The Delaware Supreme Court ruling not only banned direct shareholder claims under Gentile, but also rejected their alternative argument for direct ownership based on interference with their voting rights. The judges said the specific facts of the case did not support the theory of voting rights.

Shareholder lawyers Steven Purcell and Douglas Julie of Purcell Julie & Lefkowitz did not respond to my email question about the ruling.

Weil Gotshal’s termination brief in the Brookfield case relied heavily on a concurring opinion from then-Chief Justice Leo Strine in 2016 El Paso Pipeline GP Co LLC v. Brinckerhoff. By this time, Chancellery Court justices had begun to expand the limits of the Supreme Court’s ownership interest in Gentile, allowing shareholders to bring direct dilution claims against board members as well as controlling shareholders, believing that it made no sense to keep controlling shareholders at a higher than corporate directors.

El Paso involved extremely unusual facts. Shareholders arguing derivative claims won a first-instance ruling that found the board of directors approved a deal favoring the controlling general partner of the company. After the trial, however, the plaintiffs lost the quality of their derivative claims when the limited partnership was acquired in a merger.

The trial judge concluded that the shareholders could continue to advance their theory as a direct claim under Gentile. The Delaware Supreme Court overturned the decision, ruling that Gentile could not be extended beyond the particular circumstances of this case, in which minority shareholders would have lost both economic value and voting rights due to the actions of the controlling shareholder.

In a deal, Strine said Gentile should be thrown out completely, though he agreed the El Paso affair didn’t present the opportunity squarely. Gentile, he wrote, is “a puzzling decision, which blurs the clarity of our law in an important context,” he wrote. The precedent “cannot be reconciled with the heavy weight of our precedent,” Strine said, and purports to fill a loophole in Delaware law that is already filled by case law allowing shareholders to sue board members directly. for transactions that transfer control of a company to a majority shareholder.

“Gentile undermines the clarity and consistency that Tooley brought to determining which claims are derived from,” Strine wrote.

Weil, who declined to make a statement on Monday’s ruling, acknowledged that the Brookfield case presented an opportunity that had eluded the Delaware Supreme Court in the 2016 El Paso case. The Brookfield facts matched perfectly with those of Gentile. It was an opportunity for the court, Brookfield told the Delaware judges, to set aside the precedent that had so troubled the former chief justice.

“Practitioners and jurists have argued that the good guys should not remain a good law, and this court’s decision to clarify and harmonize the law will have no surprising or unsettling effect,” Weil argued in his brief. final of the Supreme Court. “On the contrary, the elimination of the doctrine of the status of the Gentiles will promote a more consistent and sensible application of Delaware law. “

The judges accepted. Every now and then when you swing towards the fences you manage to hit a grand slam.

The opinions expressed here are those of the author. Reuters News, under the principles of trust, is committed to respecting integrity, independence and freedom from bias.

Our standards: Thomson Reuters Trust Principles.

The opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the principles of trust, is committed to respecting integrity, independence and freedom from bias.

Source link

Should you accumulate shares of Starbucks Corporation (SBUX) on Tuesday?

Starbucks Corporation (SBUX) shares have risen 34.22% in the past 12 months, and the average rating for Wall Street analysts is Buy. Investors Observer proprietary ranking system, gives the SBUX stock a possible score of 67 out of 100. This ranking is primarily influenced by a short-term technical score of 86. The SBUX ranking also includes a long-term technical score of 71. The fundamental score for SBUX is 45. In addition to the average Wall Street analyst score , SBUX stock has an average target price of $ 128.67. This means that analysts expect the stock to rise 14.27% over the next 12 months.

SBUX has an overall score of 67. Find out what that means to you and get the rest of the leaderboard on SBUX!

What’s going on with SBUX Stock today

Shares of Starbucks Corporation (SBUX) rose 0.7% while the S&P 500 rose 0.1% at 2:05 p.m. on Tuesday, September 21. SBUX was up $ 0.78 from the previous closing price of $ 111.82 on a volume of 3,203,113 shares. Over the past year, the S&P 500 has gained 32.95% while the SBUX is up 34.22%. SBUX has earned $ 2.39 per share over the past 12 months, giving it a price-to-earnings ratio of 47.15. Click here for the full Starbucks Corporation Stock Report.

Source link

At US $ 193, is it time to put Texas Instruments Incorporated (NASDAQ: TXN) on your watchlist?

Let’s talk about the popular Texas Instruments Incorporated (NASDAQ: TXN). The company’s shares had a relatively moderate few weeks in terms of changes in stock prices, which continued to hover around US $ 183 to US $ 198. But is this the true level of valuation of large caps? Or is it currently undervalued, giving us the opportunity to buy? Let’s take a look at the outlook and value of Texas Instruments based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest review for Texas Instruments

What is Texas Instruments worth?

According to my valuation model, the stock is currently about 33% overvalued, trading at US $ 193 from my intrinsic value of $ 144.63. Not the best news for investors looking to buy! If you like the action, you might want to keep an eye out for potential price drops in the future. Since Texas Instruments’ stock price is quite volatile, this could mean that it may fall (or rise even more) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator of how the stock is moving relative to the rest of the market.

What does the future of Texas Instruments look like?

profit and revenue growth

Investors looking to grow their portfolio may want to consider the prospects of a company before buying its shares. While value investors argue that intrinsic value versus price matters most, a more compelling investment thesis would be high growth potential at a cheap price. Texas Instruments earnings growth is expected to be in the coming years, indicating a solid future. This should lead to strong cash flow, fueling a higher value of the stock.

What this means for you:

Are you a shareholder? TXN’s bullish future growth appears to have been factored into the current stock price, with stocks trading above their fair value. However, this raises another question: is now a good time to sell? If you think TXN should trade below its current price, selling high and buying it back when its price drops to its true value can pay off. But before you make that decision, check to see if its fundamentals have changed.

Are you a potential investor? If you’ve been keeping your eye on TXN for a while, it might not be the best time to enter inventory. The price has exceeded its true value, which means that there is no benefit to poor pricing. However, the positive outlook is encouraging for TXN, which means it is worth exploring other factors in order to take advantage of the next price drop.

In light of this, if you want to do more analysis on the business, it is essential to be aware of the risks involved. Example: we have spotted 2 warning signs for Texas Instruments you must be aware.

If you’re no longer interested in Texas Instruments, you can use our free platform to view our list of over 50 other high growth stocks.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative material. Simply Wall St does not have any position in the mentioned stocks.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at) simplywallst.com.

Source link